180 Life Sciences Past Earnings Performance
Past criteria checks 0/6
180 Life Sciences has been growing earnings at an average annual rate of 0.7%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
0.7%
Earnings growth rate
35.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -83.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
180 Life Sciences to raise $6.5M in direct stock offering
Jul 18180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)
Sep 08What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?
Feb 17
SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today
Nov 27Revenue & Expenses Breakdown
How 180 Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -3 | 5 | 2 |
| 30 Jun 24 | 0 | -13 | 7 | 2 |
| 31 Mar 24 | 0 | -16 | 8 | 3 |
| 31 Dec 23 | 0 | -20 | 11 | 3 |
| 30 Sep 23 | 0 | -40 | 14 | 3 |
| 30 Jun 23 | 0 | -52 | 15 | 3 |
| 31 Mar 23 | 0 | -45 | 16 | 3 |
| 31 Dec 22 | 0 | -39 | 15 | 2 |
| 30 Sep 22 | 0 | -16 | 13 | 4 |
| 30 Jun 22 | 0 | 24 | 13 | 4 |
| 31 Mar 22 | 0 | -3 | 12 | 4 |
| 31 Dec 21 | 0 | -20 | 12 | 4 |
| 30 Sep 21 | 0 | -30 | 11 | 3 |
| 30 Jun 21 | 0 | -50 | 7 | 3 |
| 31 Mar 21 | 0 | -26 | 5 | 2 |
| 31 Dec 20 | 0 | -12 | 3 | 2 |
| 30 Sep 20 | 0 | -29 | 20 | 3 |
| 30 Jun 20 | 0 | -28 | 20 | 3 |
| 31 Mar 20 | 0 | -28 | 20 | 3 |
| 31 Dec 19 | 0 | -25 | 19 | 2 |
| 30 Sep 19 | 0 | -4 | 3 | 1 |
| 30 Jun 19 | 0 | -6 | 4 | 1 |
Quality Earnings: ATNF is currently unprofitable.
Growing Profit Margin: ATNF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATNF is unprofitable, but has reduced losses over the past 5 years at a rate of 0.7% per year.
Accelerating Growth: Unable to compare ATNF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATNF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ATNF has a negative Return on Equity (-83.61%), as it is currently unprofitable.